Jennifer Barrett, Associate Editor

Caplacizumab-yhdp (Cablivi, Sanofi) is a targeted treatment designed to inhibit the formation of blood clots in adults with acquired thrombotic thrombocytopenic purpura.

Despite efforts to ease cost burden for Medicare Part D beneficiaries, high out-of-pocket costs for specialty tier drugs continue to be a concern for patients without low-income subsidies.

Medicare Part D patients can face thousands of dollars in out-of-pocket costs for a single specialty tier drug.

The global hepatitis C virus epidemic faces several barriers and meeting WHO target goals will be difficult unless a vast strategy is implemented.

Researchers have identified a link between CXCR4 expression, fibrosis, and immunosuppression in patients with metastatic breast cancer.

Scaling up prevention, treatment, and screening interventions can make substantial strides toward global hepatitis C elimination.

Officials with the FDA have expanded the label of pemetrexed for injection (Alimta, Eli Lilly) in combination with pembrolizumab (Keytruda, Merck) and platinum chemotherapy.

The approval is based on data demonstrating improved progression-free survival and overall survival in patients with metastatic nonsquamous non-small cell lung cancer.

Study evaluates whether patients with head and neck cancer who have PIK3A gene mutations could benefit from regular aspirin use.

An FDA-approved genetically modified herpes virus can effectively treat metastatic melanoma when injected into the tumor.

A targeted therapeutic approach shrank tumors caused by medulloblastoma, a deadly form a pediatric brain cancer.

Senate Finance Committee Chairman Senator Charles Grassley pledged to “get to the bottom of the insulin price problem.”

Senate Finance Committee Chairman Senator Charles Grassley pledged to “get to the bottom of the insulin price problem.”

In a congressional hearing held on Capitol Hill today, the damaging impact of rising insulin prices was the centerpiece of a larger discussion on rising drug costs in the United States.

Analysis shows prices among all insulin types and products increased steadily between 2012 and 2016.

Ibrutinub plus obinutuzumab is the first FDA-approved non-chemotherapy combination regimen for chronic lymphocytic lymphoma and small lymphocytic lymphoma.

Better strategies are needed to adequately identify and prevent opportunistic infections and related deaths in patients with advanced HIV.

Younger cancer survivors and those with high deductible private insurance plans experienced the greatest financial burden.

The new indication would allow treatment-experienced patients with HIV to switch to Pifeltro in combination with other HIV medications or Delstrigo.

Universal hepatitis screening may be warranted to identify patients with cancer who have undiagnosed viral infections.

This is the first time an anti-PD-1 therapy has demonstrated a survival benefit in this patient population.

An overview of scientific evidence supporting the HIV undetectable=untransmittable concept and implications for HIV prevention and treatment.

Study suggests a survival benefit with ibrutinib compared with chemoimmunotherapy bendamustine plus rituximab in patients with chronic lymphocytic leukemia.

Recommendations outline the efficacy of different types of therapies, dosing regimens, and routes for patients with mild-to-moderate ulcerative colitis.

Atezolizumab (Tecentriq) plus chemotherapy significantly extended survival in patients with metastatic non-squamous non-small cell lung cancer.

The target action date for the FDA’s decision on caplacizumab (Cablivi) is February 6, 2019.

Officials with the FDA today approved the first generic version of vigabatrin 500-mg tablets, which is also sold under the brand name Sabril, a medication used to treat complex partial seizures.

Zanubrutinib (BGB-3111) is being investigated for the treatment of various B-cell malignancies, including mantle cell lymphoma.

Offering screening and referrals for mental health and peer support services can improve HIV outcomes in American Indian and Alaska Native patients.

Patients with low-risk prostate cancer that harbors certain genetic alterations may have a higher risk of disease progression.